Jafron Biomedical Co.,Ltd. (SHE: 300529)

Market Cap	22.72B
Revenue (ttm)	2.63B
Net Income (ttm)	804.47M
Shares Out	774.36M
EPS (ttm)	1.01
PE Ratio	28.98
Forward PE	20.91
Dividend	0.40 (1.36%)
Ex-Dividend Date	n/a

Volume	5,229,343
Open	29.92
Previous Close	30.15
Day's Range	29.30 - 30.42
52-Week Range	15.88 - 39.24
Beta	0.33
Analysts	n/a
Price Target	n/a
Earnings Date	Apr 16, 2025

About Jafron Biomedical Co.,Ltd.

Jafron Biomedical Co.,Ltd. engages in the research, development, production, and sales of blood purification products for hemadsorption industry in China and internationally. The company offers solutions for ESRD diseases, acute poisoning, critical illness, hepatopathy, immunological disorders, kidney, and liver diseases; HA series hemoperfusion cartridge, BS bilirubin adsorption column and DNA immunoadsorption column, hemoperfusion machine, and blood purification machine; and other products, such as hemodialyzer, hemodialysis concentrate, disi...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1989
• Employees: 2,408
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300529

Financial Performance

In 2023, Jafron Biomedical Co.,Ltd.'s revenue was 1.92 billion, a decrease of -22.84% compared to the previous year's 2.49 billion. Earnings were 436.49 million, a decrease of -50.93%.